Role of proteasome inhibition in Waldenström's macroglobulinemia

Aldo Roccaro, Antonio Sacco, Xavier Leleu, Abdel Kareem Azab, Feda Azab, Judith Runnels, Xiaoying Jia, Hai Ngo, Molly Melhem, Anne Sophie Moreau, Irene Ghobrial

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The paradigm for the treatment of monoclonal gammophaties has dramatically changed: based on the understanding of the complex interaction between tumor cells and bone marrow microenvironment and the signaling pathways that are deregulated in this process, a number of novel therapeutic agents are now available. For example, 3 novel agents with a targeted anti-multiple myeloma activity, have been FDA approved for the treatment of this disease, namely bortezomib, thalidomide, and lenalidomide. The success of targeted therapy in myeloma has led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström's macroglobulinemia (WM), both in the preclinical settings and as part of clinical trials. Among them the role of proteasome inhibitors has been widely dissected providing the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM.

Original languageEnglish
Pages (from-to)94-96
Number of pages3
JournalClinical Lymphoma and Myeloma
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Keywords

  • Angiogenesis
  • Bortezomib
  • Immune response
  • NPI-0052
  • Waldenström

Fingerprint Dive into the research topics of 'Role of proteasome inhibition in Waldenström's macroglobulinemia'. Together they form a unique fingerprint.

  • Cite this

    Roccaro, A., Sacco, A., Leleu, X., Azab, A. K., Azab, F., Runnels, J., Jia, X., Ngo, H., Melhem, M., Moreau, A. S., & Ghobrial, I. (2009). Role of proteasome inhibition in Waldenström's macroglobulinemia. Clinical Lymphoma and Myeloma, 9(1), 94-96. https://doi.org/10.3816/CLM.2009.n.025